Cite
MLA Citation
Igor Puzanov et al.. “433 Talimogene laherparepvec (T-VEC) in combination with ipilimumab (IPI) versus IPI alone for advanced melanoma: 4-year interim analysis of a randomized, open-label, phase 2 trial.” Journal for immunotherapy of cancer, vol. 8, n.d., pp. A263–A264. http://access.bl.uk/ark:/81055/vdc_100144722043.0x000004